Cathepsin K, an important molecule in bone collagen matrix resorption, and the serum level of RANKL and RANKL/OPG ratio are significantly reduced in MM patients receiving lenalidomide treatment. This evidence concerns the gene TNFRSF11B and Miyoshi myopathy.